COVID-19 is a fast-moving pandemic. The infection has a mortality rate of 3-6%. Patients with underlying CVD are at higher risk of contracting COVID-19 and have a worse prognosis.
Our experts from Wuhan China and Singapore have shared clinical experiences from frontline China on management of COVID-19 patients with underlying heart disease. Topics include:
- Diagnosis to management of COVID-19 patients with underlying CVD: Learnings from China
- COVID-19 and Anti-hypertensive Drugs
- Clinical Case sharing – experience from Singapore
Professor Zhou Ning – Clinical Characteristics and Management of COVID-19 Patients
Professor Koji Hasegawa – COVID-19 and Anti-hypertensive Drugs
Dr Ling Li Min – Clinical Case Sharing – Experiences from Singapore
Panel discussion
